Share This Page
SCANDONEST PLAIN Drug Patent Profile
✉ Email this page to a colleague
When do Scandonest Plain patents expire, and when can generic versions of Scandonest Plain launch?
Scandonest Plain is a drug marketed by Deproco and is included in one NDA.
The generic ingredient in SCANDONEST PLAIN is mepivacaine hydrochloride. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mepivacaine hydrochloride profile page.
US Patents and Regulatory Information for SCANDONEST PLAIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deproco | SCANDONEST PLAIN | mepivacaine hydrochloride | INJECTABLE;INJECTION | 088387-001 | Oct 10, 1984 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
SCANDONEST PLAIN (articaine/epinephrine) Investment Scenario and Patent/Regulatory Fundamentals Analysis
Scandonest Plain (articaine hydrochloride + epinephrine bitartrate) is an injectable local anesthetic marketed for dental procedures. For an investment-grade view, the key drivers are (1) patent and exclusivity barriers around the exact strength and formulation in target geographies, (2) FDA or equivalent regulator status by country for this specific branded presentation, (3) competitive intensity from local anesthetic generics and cartridge-system products, and (4) distribution and tender pricing rather than specialty-market adoption.
The practical conclusion: an investor’s near- to mid-term upside is typically constrained for a mature, off-patent dental anesthetic unless the company controls a defensible product presentation (cartridge format, needle regimen, or specific label/regulatory dossier strategy) and can sustain margins through contracting and supply scale.
What is Scandonest Plain and what market factors drive revenue?
Featured snippet answer: Scandonest Plain is a dental injectable local anesthetic containing articaine with epinephrine. Revenue is driven by dental procedure volume, tender and distributor pricing, and share of clinic and institutional accounts more than by breakthrough clinical differentiation.
How Scandonest Plain is positioned clinically
- Indication focus: local anesthesia for dental procedures (typical use case across articaine products).
- Differentiators that matter commercially:
- patient experience and onset profile within the articaine class
- compatibility with dental delivery systems (cartridges, syringe/ampoule formats)
- dosing and label language that supports routine prescribing by dental practitioners
What moves demand
- Dental capex cycles and volume: restorative work, endodontics, and elective procedures.
- Reimbursement and procurement: many markets use pharmacy or clinic procurement, shifting the economics toward contract pricing.
- Inventory cycles: local anesthetics face frequent distributor reallocations.
What investors should model for margins
- Gross margin sensitivity to:
- generic price compression in local anesthetic categories
- input costs (API and packaging)
- logistics and cold-chain needs (if any for the specific presentation in a given country)
- EBITDA sensitivity to:
- distributor commissions
- pharmacovigilance and regulatory maintenance costs
- market authorization renewals and line extensions
Investment lens: For Scandonest Plain, the revenue and margin curve is usually governed by generic penetration speed and the ability to defend the product’s labelling, format, and distribution footprint.
What patents protect Scandonest Plain (articaine/epinephrine) and how strong is the estate?
Featured snippet answer: Patent protection for Scandonest Plain typically rests, if at all, on formulation, specific salt combinations/concentrations, and packaging or manufacturing methods. For widely used articaine products, core composition patents are often out of date in many jurisdictions; the value is usually in any remaining presentation-specific patents or local regulatory exclusivity windows.
Patent estate components investors should test
- Composition-of-matter (articaine + epinephrine salts and defined concentrations)
- Formulation patents
- pH range
- stabilizers/antioxidants
- solubility and shelf-life improvements
- Method-of-manufacture
- sterilization and impurity control
- Packaging/presentation
- cartridge format
- needle compatibility and dosing regimen
- Regulatory exclusivity
- data exclusivity if a specific reference application is still within the window (depends on country and regulatory history)
What “strong estate” would look like for an injectable dental anesthetic
- Remaining enforceable patents with narrow but commercially meaningful claim coverage, such as:
- a specific strength for dental cartridges in a defined container system
- a manufacturing method that generics cannot replicate without process design-arounds
- an improvement patent that supports label language required for tender acceptance
Core risk profile
- High probability of generic availability in many markets for articaine/epinephrine injections.
- Enforcement asymmetry: even when patents exist, the market impact depends on whether generics are blocked from the exact presentation and whether courts/enforcement are active.
When does Scandonest Plain lose exclusivity and what are the expiration scenarios by region?
Featured snippet answer: Exclusivity loss for Scandonest Plain is usually driven by:
- composition/formulation patent expirations, and
- whether any jurisdiction still grants data or market exclusivity for the specific product strength and presentation.
Modeling framework for expiration scenarios
- Scenario A: composition patents expired
- Generics can usually file and market versions based on abbreviated regulatory routes, with only labeling/presentation constraints.
- Scenario B: formulation/presentation patents still active
- Patent enforcement can delay entry for specific formats/strengths.
- Scenario C: regulatory exclusivity still active
- Entry may be delayed even if patents are weak, depending on data exclusivity rules.
Investment takeaway: Without a clear, present-tense map of enforceable patents and regulatory exclusivity by country for the exact Scandonest Plain presentation, risk for generic erosion is the base case. The upside case requires remaining enforceable presentation-level IP.
What generic entry risks exist for Scandonest Plain under Paragraph IV or local equivalents?
Featured snippet answer: In the US system, Paragraph IV challenges apply to ANDA products referencing an Orange Book-listed reference drug. For Scandonest Plain, the generic entry risk depends on whether it has an FDA-approved reference listing that is Orange Book-active and whether relevant patents are listed.
US-specific entry mechanics (how to frame the risk)
- If Scandonest Plain is not FDA-listed with active Orange Book patents for the exact dosage form/strength, Paragraph IV is not the main threat.
- If it is Orange Book-listed, generics can:
- file ANDAs via section viii (or other eligible pathways)
- make patent certifications and potentially file Paragraph IV challenges
Practical generic threats in dental anesthetics
- Direct generic substitution: same active salts and similar concentration.
- Presentation swap: different container/needle configuration that still meets procurement needs.
- NDC-based listing strategies: targeting the specific package sizes used by clinics.
Investment conclusion: Generic entry risk is typically high in mature local anesthetics unless the brand controls a uniquely tenderable presentation protected by enforceable patents.
What is the Orange Book status of Scandonest Plain and what patents are listed?
Featured snippet answer: Orange Book status is decisive for US entry risk. The investment decision requires knowing whether Scandonest Plain has active Orange Book-listed patents tied to the exact strength, dosage form, and route.
What to look for in Orange Book listings
- Drug product identifier: strength and dosage form match
- Patent categories:
- 1: composition claims
- 2: method of use claims
- 3: formulation
- 4: method of manufacture
- 5: FDA-required for conditions of approval
- 6: pediatric extension
- Expiration dates and earliest listed date
- Multiple patents per NDC indicating layered barriers
Investment lens: If listings show layered patents with later expirations, generics face a narrower “design-around” window. If listings are absent or short-lived, market share erosion is likely to follow generic availability.
Which companies are challenging Scandonest Plain and what litigation affects entry timing?
Featured snippet answer: The threat profile for Scandonest Plain depends on whether there are:
- active ANDA Paragraph IV filings in jurisdictions that use US-style patent litigation,
- or equivalent opposition actions in Europe (centralized or national), Canada, and other markets.
What litigation would do to the investment model
- delay “first generic” marketing by triggering automatic stays (US) or injunctions
- force settlements that define launch calendars and licensed exclusivity terms
How to quantify impact
- stay and settlement date windows
- stipulated launch at-risk dates
- damages exposure and indemnity scope
Investment conclusion: For an injectable dental anesthetic, litigation is usually infrequent unless the patent estate is actively enforced against specific presentations. The business outcome is still dominated by procurement pricing and distributor stocking.
What settlement agreements and licensing deals shape the commercialization timeline?
Featured snippet answer: For mature anesthetics, licensing is most common where patent claims are specific to a formulation/presentation and the brand can secure a market carve-out or controlled launch.
Settlement deal terms investors should demand in diligence
- effective start date for generic launch
- scope: which NDCs/strengths/packages
- payments and royalties
- “carve-out” clauses allowing other competitors to launch non-covered strengths
- duration and termination triggers
Investment lens: A licensing deal can preserve revenue longer than patents alone, but only if it covers the most widely procured presentation(s).
What formulations are protected for Scandonest Plain and how do they block biosimilar-like competition?
Featured snippet answer: Scandonest Plain is a small-molecule injectable local anesthetic. Biosimilar concepts do not apply. The formulation IP protection that matters is tied to generic substitutes: concentration, pH, antioxidants, and container/closure compatibility.
Formulation protection categories relevant to generics
- defined salt ratio and concentration
- stabilizers preventing oxidation of epinephrine
- sterility assurance methods and impurity specifications
- shelf-life improvements validated in stability data
Design-around reality check
- Generic entrants can often change:
- pH within safe bounds
- stabilizer system within pharmacopeia constraints
- manufacturing process while meeting specs Unless claims are tight, design-arounds are feasible.
Investment conclusion: Formulation IP is valuable only when claims are narrow enough to prevent substitution at procurement-accepted specs.
How does Scandonest Plain compare with other articaine/epinephrine dental anesthetics on price and IP barriers?
Featured snippet answer: Within articaine/epinephrine local anesthetics, branded differentiation is usually limited. IP barriers are typically weak post-expiry, leaving the market to compete on pricing, procurement access, and packaging compatibility.
Comparison dimensions for an investor model
- time since brand launch in each geography
- number of marketed alternatives (generics and other branded articaine products)
- tender frequency and buyer consolidation in dental networks
- distributor power and private label presence
Competitive landscape structure
- “same active + same concentration” generics often dominate once available
- branded products can persist where:
- they have preferred procurement contracts
- product form factors reduce dosing errors or improve convenience
- the brand maintains supply reliability
Investment takeaway: The competitive equilibrium often becomes pricing-led after generic entry, with modest brand premium only where contracts lock in usage.
Is Scandonest Plain affected by manufacturing and IP barriers for generics?
Featured snippet answer: For injectable local anesthetics, manufacturing/IP barriers are usually practical and procedural rather than structural. Key risk is whether the brand’s method-of-manufacture patents or stability/sterility process IP are enforceable for the exact presentation.
Manufacturing bottlenecks that can slow generic entry
- sterility assurance and batch consistency for epinephrine-stabilized solutions
- impurity control and validated stability windows
- packaging line qualification for specific cartridges/syringes
Typical investor risk adjustment
- even with patent barriers, generics can sometimes enter if:
- process patents are weak or invalidated
- regulators accept equivalent stability profiles
- procurement buyers allow substitution
Regulatory approval status: what is the FDA or equivalent pathway for Scandonest Plain?
Featured snippet answer: For US-focused analysis, the critical factor is whether Scandonest Plain is FDA-approved with an Orange Book-listed reference product for the exact dosage form/strength. For other geographies, the equivalent is whether it remains the reference authorization with ongoing data or marketing exclusivity.
Pathway implications for investors
- If referenced product is mature with no active exclusivity, generics can use abbreviated or bibliographic routes.
- If specific regulatory data protections exist, entry timing can shift even when patents are weak.
Investment conclusion: The decisive diligence step is mapping regulatory exclusivity to the exact product strength and presentation; otherwise revenue erosion modeling is unreliable.
Commercial fundamentals: what revenue and cash-flow profile fits Scandonest Plain?
Featured snippet answer: Scandonest Plain fits a “mature branded consumable” profile. Cash flows are driven by distribution reach, procurement wins, and supply scale, with limited upside from R&D unless a portfolio expansion exists (line extensions, new strengths, new formats, or combination products).
Revenue drivers to quantify in diligence
- units sold per quarter by geography
- average net selling price trend versus generic substitutes
- channel mix: dental clinics, hospitals, distributors, tenders
- customer concentration and contract duration
Cost structure
- COGS dominated by API and packaging (including cartridges and closures)
- SG&A driven by sales force and distributor commissions
- regulatory and pharmacovigilance costs per market authorization
Key downside
- rapid price compression once generic substitution becomes available at scale
- inventory holding costs if product demand falls faster than supply planning
What would an investor underwrite: base case vs upside vs downside?
Featured snippet answer: Base case is generic substitution-driven margin compression after exclusivity and/or patent barriers expire. Upside requires remaining enforceable presentation-level IP plus sustained procurement preference. Downside assumes early generic entry and aggressive price reductions.
Base case (most likely for mature anesthetic brands)
- limited patent-driven protection
- steady unit decline over time
- net price drop following generic entry and tender repricing
Upside case
- remaining enforceable patents covering:
- specific strength, container system, or formulation stabilizer
- active litigation or settlement preserves market share longer
- supply reliability and contract lock-in support premium pricing
Downside case
- fast generic substitution in the top procurement markets
- loss of preferred distributor contracts
- increased returns and inventory obsolescence
Key Takeaways
- Scandonest Plain is a mature small-molecule injectable dental anesthetic. The investment thesis is dominated by competitive generic substitution and procurement economics rather than breakthrough innovation.
- The only meaningful IP upside comes from remaining enforceable patents tied to the exact formulation strength, container/presentation, or specific manufacturing/stability claims in key geographies.
- Exclusivity and Orange Book-style regulatory listings control US-style generic entry risk; equivalent regulatory authorization and data exclusivity control in other markets.
- Litigation and settlements matter only if they preserve the specific commercial presentation used in tenders and high-volume accounts.
- Investors should underwrite a base case of price pressure and model upside only on enforceable, presentation-specific barriers and contract durability.
FAQs
1) How fast do generics typically penetrate articaine/epinephrine dental anesthetics after approval?
Penetration speed depends on availability of equivalent presentations (strength and container format), procurement tender cycles, and distributor switching behavior; market share often shifts quickly once multiple low-priced options are stocked.
2) Do patents on articaine/epinephrine generally prevent generics of the same active ingredients?
Often no, once core composition patents expire; protection usually narrows to formulation process, specific concentrations, or presentation-level features that must be matched.
3) What procurement terms matter most for Scandonest Plain profitability?
Unit price and contract duration, substitution clauses, and tender eligibility tied to NDC/product code and container format are the main levers.
4) How should an investor model litigation risk for a mature dental anesthetic brand?
Model the impact as a set of entry-delay probabilities tied to specific NDC/strength coverage, settlement terms, and the likelihood of injunction or stay enforcement in the relevant jurisdictions.
5) What KPIs best predict whether Scandonest Plain revenue will decline after generic entry?
Net selling price trend vs generic benchmarks, unit share in top dental network contracts, distributor inventory behavior, and the time-to-tender repricing after generic launch.
References
- https://www.accessdata.fda.gov/scripts/cder/ob/ (FDA Orange Book)
- https://www.fda.gov/drugs/ (FDA drug regulatory resources)
- https://www.ema.europa.eu/ (European Medicines Agency regulatory resources)
More… ↓
